The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5 million per...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019 Epidiolex U.S. year to date net sales of $188.0 million, including Q3...
The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$7.5 million per...
GW Pharmaceuticals receives European Commission approval for EPIDYOLEX® (cannabidiol) for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy Cannabidiol oral solution is the...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$5.0 million per quarter. This...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Second Quarter Ended June 30, 2019 Epidiolex U.S. Q2 net sales of $68.4 million Positive CHMP opinion clears...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$5.0 million per quarter. This...
After a 57.4% rebound in Q1 followed by a narrow decline in April, Cannabis stocks, as measured by the Global Cannabis Stock Index, gave up substantial ground in May, declining...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$5.0 million per quarter. This...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019 Epidiolex U.S. Q1 net sales of $33.5m Positive Phase 3 pivotal results...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$5.0 million per quarter. This...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Quarter Ended December 31, 2018 Epidiolex® (cannabidiol) oral solution (CV), first FDA-approved plant-derived cannabinoid medicine, launched in the...
A post on Twitter today has pressured GW Pharma (NASDAQ: GWPH), which dipped more than 3% to $145.21. The post, by Ryan Flinn, a Bay Area journalist in healthcare...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome – Primary endpoint achieved with both EPIDIOLEX doses compared...
This article was published originally at 420 Investor in October A highly disruptive technology that I have discussed over the past few years appears to be gaining traction. Biosynthesis,...
Aphria (TSX: APH) (OTC: APHQF) has filed a Form 40-F that reveals it is intending to list on the New York Stock Exchange: The company will join an exclusive...
Aurora Cannabis (TSX: ACB) (OTC: ACBFF) has publicly disclosed that it will be listing on a major exchange in the United States in October, but, until today, the exchange...
GW Pharmaceuticals plc Announces Pricing of Public Offering of ADSs Raising Gross Proceeds of $300 Million LONDON and CARLSBAD, Calif., Oct. 02, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc...
GW Pharmaceuticals Announces Proposed Public Offering of ADSs LONDON and CARLSBAD, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”),...
Cannabis stocks, as measured by the Global Cannabis Stock Index, added to their August gains in September, rising 2.4% to 114.83: The index, which had 53 qualifying members that were...
The DEA has given Epidiolex, the CBD-based pharmaceutical derived from cannabis that was approved by the FDA for the treatment of rare forms of epilepsy in June, Schedule V...
The Public Cannabis Company Revenue Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis stocks that generate industry sales of more than US$2.5 million per quarter. This...
